Vaxcyte CEO surrenders 17K shares for taxes

Vaxcyte’s CEO used shares to satisfy RSU tax obligations while retaining a sizable direct and trust-based stake.

Available on EDGAR 09/09/2026 - 05:56 PM EDT Accepted by SEC EDGAR 09/09/2026 - 05:56 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reports that Chief Executive Officer and director Grant Pickering surrendered 17,056 shares of Common Stock on September 8, 2026 to cover applicable tax withholding obligations arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he directly holds 429,902 shares of Vaxcyte common stock and also has indirect holdings through trusts established for his son and daughter.

Insider Trade Summary

Tax Withholding: 17,056 shares

Tax Withholding 1 txn

Insider PICKERING GRANT

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	17,056	$60.36	$1.03M
Holding	Common Stock F2	--	--	--
Holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 429,902 shares (Direct); Common Stock — 266,430 shares (Indirect, By Children's Trust)

Footnotes (3)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
2. F2. Shares are held directly by a trust for the benefit of the Reporting Person's son.
3. F3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

Key Figures

Shares surrendered for tax withholding: 17,056 shares Reference price per share: $60.36 per share Direct holdings after transaction: 429,902 shares +1 more

4 metrics

Shares surrendered for tax withholding 17,056 shares Common Stock surrendered on September 8, 2026 to cover RSU tax obligations

Reference price per share $60.36 per share Price applied to the 17,056-share tax-withholding disposition

Direct holdings after transaction 429,902 shares Common Stock directly held by Grant Pickering following the September 8, 2026 transaction

Tax-withholding disposition shares 17,056 shares Reported under a transaction coded as payment of tax liability by delivering or withholding securities

Key Terms

restricted stock units, tax withholding obligations, indirect ownership

3 terms

restricted stock units financial

"tax withholding obligations realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares surrendered to the Issuer to cover applicable tax withholding obligations"

indirect ownership financial

"Shares are held directly by a trust for the benefit of the Reporting Person's son"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) CEO Grant Pickering report in this Form 4?

He reported that 17,056 shares of Vaxcyte Common Stock were surrendered on September 8, 2026 to cover tax withholding obligations triggered by the vesting of restricted stock units, at a reference price of $60.36 per share.

Did the Vaxcyte (PCVX) CEO sell shares in the open market?

No. The Form 4 describes a tax-withholding disposition, where 17,056 shares were surrendered to the issuer to satisfy RSU-related tax liabilities, rather than a discretionary open-market sale.

How many Vaxcyte (PCVX) shares does the CEO hold after this transaction?

Following the September 8, 2026 transaction, Grant Pickering directly holds 429,902 shares of Vaxcyte Common Stock. He also has additional indirect holdings through trusts for the benefit of his son and daughter.

Was the Vaxcyte (PCVX) CEO’s transaction under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 plan is reported for this transaction; the document-level checkbox for such a plan is marked as not applicable.

How are the Vaxcyte (PCVX) CEO’s children’s trust holdings described?

The filing notes that some Vaxcyte shares are held indirectly by trusts for the benefit of the CEO’s son and daughter. These positions are reported as indirect ownership and are separate from his 429,902 directly held shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PICKERING GRANT

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		F		17,056(1)	D	$60.36	429,902	D
Common Stock								133,215	I	By Children's Trust(2)
Common Stock								133,215	I	By Children's Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

2. Shares are held directly by a trust for the benefit of the Reporting Person's son.

3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

Remarks:

	Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)